{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:57:37Z","timestamp":1785041857962,"version":"3.55.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.revmed.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T12:41:35Z","timestamp":1695127295000},"page":"495-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-9043","authenticated-orcid":false,"given":"Z.","family":"Amoura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bader-Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"BAL dit Sollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bezanahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Darnige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Elefant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Harroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Martin-Toutain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pineton De Chambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Pontual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zuily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Clouscard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Frere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kone-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lasne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Le Guern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ni Zard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schleinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2023.08.004_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N","article-title":"Validation of the Sapporo criteria for anti-phospholipid syndrome","volume":"43","author":"Lockshin","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.08.004_bib0010","article-title":"2023 American College of Rheumatology (ACR)\/European alliance of associations for rheumatology (EULAR) Antiphospholipid syndrome classification criteria","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2023.08.004_bib0015","doi-asserted-by":"crossref","first-page":"102913","DOI":"10.1016\/j.autrev.2021.102913","article-title":"Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Bernardoff","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.revmed.2023.08.004_bib0020","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.revmed.2023.08.004_bib0025","doi-asserted-by":"crossref","first-page":"CLXIII","DOI":"10.1177\/2396987321992905","article-title":"European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack","volume":"6","author":"Fonseca","year":"2021","journal-title":"Eur Stroke J"},{"issue":"11","key":"10.1016\/j.revmed.2023.08.004_bib0030","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/art.41777","article-title":"Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality","volume":"73","author":"Gendron","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"27","key":"10.1016\/j.revmed.2023.08.004_bib0035","first-page":"2137","article-title":"Updated European heart rhythm association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summar","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.revmed.2023.08.004_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.revmed.2017.02.006","article-title":"Laboratory diagnosis of antiphospholipid syndrome: from criteria to practice","volume":"39","author":"Joste","year":"2018","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2023.08.004_bib0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2019.11.001","article-title":"Potential usefulness of activated charcoal (DOAC Remove\u00ae) for DRVVT testing in patients receiving direct oral anticoagulants","volume":"184","author":"Jourdi","year":"2019","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.revmed.2023.08.004_bib0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation Guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"issue":"2","key":"10.1016\/j.revmed.2023.08.004_bib0055","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/rth2.12071","article-title":"The impact of repeated freeze-thaw cycles on antiphospholipid antibody titer","volume":"2","author":"Maelegheer","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.revmed.2023.08.004_bib0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MD.0b013e31826b971f","article-title":"Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature","volume":"91","author":"Mazodier","year":"2012","journal-title":"Medicine"},{"issue":"17","key":"10.1016\/j.revmed.2023.08.004_bib0065","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"\u201cIncidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study\u201d","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.revmed.2023.08.004_bib0070","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"9751","key":"10.1016\/j.revmed.2023.08.004_bib0075","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.revmed.2023.08.004_bib0080","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.revmed.2023.08.004_bib0085","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.revmed.2023.08.004_bib0090","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/jth.13481","article-title":"Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH","volume":"14","author":"Tripodi","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2023.08.004_bib0095","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1177\/096120339800700214","article-title":"The catastrophic anti-phospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment","volume":"7Suppl. 2","author":"Asherson","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0100","first-page":"508","article-title":"The catastrophic anti-phospholipid syndrome","volume":"19","author":"Asherson","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic anti-phospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic anti-phospholipid syndrome. Clinical and laboratory features of 50 patients","volume":"77","author":"Asherson","year":"1998","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2023.08.004_bib0115","first-page":"346","article-title":"The clinical spectrum of catastrophic anti-phospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic anti-phospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0125","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"European Forum on Anti-phospholipid Antibodies. Mortality in the catastrophic anti-phospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.08.004_bib0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic anti-phospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2023.08.004_bib0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th International Congress on anti-phospholipid antibodies task force report on catastrophic anti-phospholipid syndrome","volume":"13","author":"Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0961203310395051","article-title":"Task Force on catastrophic anti-phospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225495","article-title":"Catastrophic anti-phospholipid syndrome causing ST-segment elevation myocardial infarction with non-obstructive coronary arteries","volume":"12","author":"Cranley","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.revmed.2023.08.004_bib0150","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jfo.2014.05.024","article-title":"Severe vaso-occlusive chorioretinopathy in a patient with catastrophic anti-phospholipid antibody syndrome secondary to systemic lupus erythematosus","volume":"38","author":"Drimbea","year":"2015","journal-title":"J Fr Ophthalmol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic anti-phospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"Erkan","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.semarthrit.2012.05.005","article-title":"Relapsing catastrophic anti-phospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses","volume":"42","author":"Espinosa","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.08.004_bib0165","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/rheumatology\/key228","article-title":"Eculizumab for catastrophic anti-phospholipid syndrome-a case report and literature review","volume":"57","author":"Guillot","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.08.004_bib0170","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/CIRCULATIONAHA.113.007417","article-title":"Myocardial catastrophe: a case of sudden, severe myocardial dysfunction","volume":"130","author":"Hucker","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2023.08.004_bib0175","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.nephro.2016.07.455","article-title":"Central retinal vein occlusion in a patient on hemodialysis secondary to anti-phospholipid syndrome: case report","volume":"13","author":"Jabrane","year":"2017","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.revmed.2023.08.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226463","article-title":"Bilateral central retinal artery occlusion from catastrophic anti-phospholipid syndrome","volume":"2018","author":"Joshi","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.revmed.2023.08.004_bib0185","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.jaut.2019.06.003","article-title":"CAPS criteria fail to identify most severely-ill thrombotic anti-phospholipid syndrome patients requiring intensive care unit admission","volume":"103","author":"Pineton de Chambrun","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2023.08.004_bib0190","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.chest.2019.11.010","article-title":"In-hospital mortality-associated factors in patients with thrombotic anti-phospholipid syndrome requiring ICU admission","volume":"157","author":"Pineton de Chambrun","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2023.08.004_bib0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1759720X14554793","article-title":"Rituximab and its therapeutic potential in catastrophic anti-phospholipid syndrome","volume":"7","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.revmed.2023.08.004_bib0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.08.004_bib0205","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic anti-phospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0210","first-page":"206906","article-title":"Catastrophic anti-phospholipid syndrome presenting as bilateral central retinal artery occlusions","volume":"2015","author":"Saraf","year":"2015","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.revmed.2023.08.004_bib0215","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3899\/jrheum.161364","article-title":"Longterm outcome of patients with primary anti-phospholipid syndrome: a retrospective multicenter study","volume":"44","author":"Taraborelli","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0220","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/kem158","article-title":"The abdominal manifestations of the anti-phospholipid syndrome","volume":"46","author":"Uthman","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.08.004_bib0225","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic anti-phospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2023.08.004_bib0230","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.semarthrit.2013.07.001","article-title":"Autism spectrum disorders in babies born to mothers with anti-phospholipid syndrome","volume":"43","author":"Abisror","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.08.004_bib0235","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European Registry on Obstetric Anti-phospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases","volume":"18","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0240","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1542\/peds.2008-1209","article-title":"Pediatric anti-phospholipid syndrome: clinical and immunologic features of 121 patients in an international registry","volume":"122","author":"Avcin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.revmed.2023.08.004_bib0245","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.thromres.2008.07.012","article-title":"KIDCLOT: the importance of validated educational intervention for optimal long term warfarin management in children","volume":"123","author":"Bauman","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.revmed.2023.08.004_bib0250","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric anti-phospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2023.08.004_bib0255","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10875-019-00643-2","article-title":"IKZF1 loss-of-function variant causes autoimmunity and severe familial anti-phospholipid syndrome","volume":"39","author":"Dieudonn\u00e9","year":"2019","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0260","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-05-0340","article-title":"Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial","volume":"106","author":"Gris","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2023.08.004_bib0265","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/annrheumdis-2016-211001","article-title":"European evidence-based recommendations for diagnosis and treatment of paediatric anti-phospholipid syndrome: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.08.004_bib0270","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.arcped.2015.08.007","article-title":"Association between the presence of anti-phospholipid antibodies and the occurrence of autism spectrum disorder in childhood","volume":"22","author":"Lageix","year":"2015","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.revmed.2023.08.004_bib0275","first-page":"446","article-title":"Mothers\u2019 anti-phospholipid antibodies during pregnancy and the relation to offspring outcome","volume":"32","author":"Mekinian","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.autrev.2014.08.040","article-title":"Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/annrheumdis-2011-201167","article-title":"European registry of babies born to mothers with anti-phospholipid syndrome","volume":"72","author":"Mekinian","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.08.004_bib0290","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2023.08.004_bib0295","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2023.08.004_bib0300","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jth.12763","article-title":"Recommendations for the development of a dedicated pediatric anticoagulation service: communication from the SSC of the ISTH","volume":"13","author":"Newall","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2023.08.004_bib0305","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.thromres.2005.08.004","article-title":"Home INR monitoring of oral anticoagulant therapy in children using the CoaguChek S point-of-care monitor and a robust education program","volume":"118","author":"Newall","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.revmed.2023.08.004_bib0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-020-00976-7","article-title":"Pediatric anti-phospholipid syndrome: from pathogenesis to clinical management","volume":"23","author":"Rosina","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2023.08.004_bib0315","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/09612033211002256","article-title":"Identifying additional risk factors for arterial and venous thrombosis among pediatric anti-phospholipid antibodies carriers","volume":"30","author":"Sloan","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11926-020-0887-9","article-title":"Pediatric APS: state of the art","volume":"22","author":"Soybilgic","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2023.08.004_bib0325","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fped.2018.00362","article-title":"The differences between childhood and adult onset anti-phospholipid syndrome","volume":"6","author":"Wincup","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.revmed.2023.08.004_bib0330","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary anti-phospholipid syndrome","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0335","first-page":"598","article-title":"Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary anti-phospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL","volume":"46","author":"Mekinian","year":"2018","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-021-01006-w","article-title":"Which hormones and contraception for women with APS? Exogenous hormone use in women with APS","volume":"23","author":"Sammaritano","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2023.08.004_bib0345","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2023.08.004_bib0350","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with anti-phospholipid antibodies","volume":"14","author":"Arnaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0355","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with anti-phospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0360","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for anti-phospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.08.004_bib0365","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the anti-phospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic anti-phospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.08.004_bib0370","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of anti-phospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0375","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0961203317731532","article-title":"Risk of developing anti-phospholipid antibodies following viral infection: a systematic review and meta-analysis","volume":"27","author":"Abdel-Wahab","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0380","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/acr.24520","article-title":"Development of a new international anti-phospholipid syndrome classification criteria phase I\/II report: generation and reduction of candidate criteria","volume":"73","author":"Barbhaiya","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2023.08.004_bib0385","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11739-009-0316-6","article-title":"Presence of low titre of anti-phospholipid antibodies in cancer patients: a prospective study","volume":"4","author":"Bazzan","year":"2009","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.revmed.2023.08.004_bib0390","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/clinchem\/45.11.2007","article-title":"False-positive reactions for IgA anti-phospholipid and anti-beta(2)-glycoprotein I antibodies in patients with IgA monoclonal gammopathy","volume":"45","author":"Bizzaro","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.revmed.2023.08.004_bib0395","doi-asserted-by":"crossref","first-page":"102395","DOI":"10.1016\/j.autrev.2019.102395","article-title":"Anti-phospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"18","author":"Chock","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0400","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/ijlh.13094","article-title":"Extended persistence of anti-phospholipid antibodies beyond the 12-week time interval: Association with baseline anti-phospholipid antibodies titres","volume":"41","author":"Devignes","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0405","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/anti-phospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2023.08.004_bib0410","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40744-020-00273-w","article-title":"Anti-phospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence","volume":"8","author":"El Hasbani","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.revmed.2023.08.004_bib0415","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-021-01029-3","article-title":"Systematic review of anti-phospholipid antibodies in COVID-19 patients: culprits or bystanders?","volume":"23","author":"Foret","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2023.08.004_bib0420","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3899\/jrheum.200513","article-title":"Anti-phospholipid antibody profile stability over time: prospective results from the APS ACTION clinical database and repository","volume":"48","author":"Gkrouzman","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0425","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2023.08.004_bib0430","doi-asserted-by":"crossref","first-page":"e0227836","DOI":"10.1371\/journal.pone.0227836","article-title":"Prevalence of anti-phospholipid antibodies in Beh\u00e7et's disease: a systematic review and meta-analysis","volume":"15","author":"Islam","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2023.08.004_bib0435","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0961203310393379","article-title":"IgM, but not IgA rheumatoid factor interferes with anti-cardiolipin and anti-\u03b22 glycoprotein I measurements: a quantitative analysis","volume":"20","author":"Lakos","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0440","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semarthrit.2016.10.004","article-title":"Clinical relevance of anti-phospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis","volume":"46","author":"Merashli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.08.004_bib0445","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ard.2004.034231","article-title":"Prevalence of the anti-phospholipid syndrome in primary systemic vasculitis","volume":"65","author":"Rees","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.08.004_bib0450","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3389\/fimmu.2018.02457","article-title":"Prevalence and clinical associations of anti-phospholipid antibodies in systemic sclerosis: new data from a French cross-sectional study, systematic review, and meta-analysis","volume":"9","author":"Sobanski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0455","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of anti-phospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.08.004_bib0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of anti-phospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"\u00dcnl\u00fc","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0465","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Anti-phospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.revmed.2023.08.004_bib0470","doi-asserted-by":"crossref","DOI":"10.1177\/0961203320940776","article-title":"Cluster analysis for the identification of clinical phenotypes among anti-phospholipid antibody-positive patients from the APS ACTION Registry","author":"Zuily","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2023.08.004_bib0475","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2017.04.003","article-title":"Anti-phospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: a systematic review and meta-analysis","volume":"16","author":"Zuily","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.08.004_bib0480","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.111.028522","article-title":"Increased risk for heart valve disease associated with anti-phospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies","volume":"124","author":"Zuily","year":"2011","journal-title":"Circulation"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323007117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323007117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:03Z","timestamp":1759337223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323007117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0248866323007117"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.08.004","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}